Paul A. Wagner is SEE REMARKS at Forte Biosciences, Inc. (FBRX). They have made 8 open-market trades across 1 company since 2020, most recently 2026-07-01.
CIK 0001612842
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
7 open-market purchases totalling $339K since 2020, against 1 sale. Across 7 scored buys the stock is up 43.3% at ninety days, and 34.2 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| FBRX | 85,482 | $6.6M |
Shares reported on the most recent Form 4, priced at the 2026-07-06 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 86% | 71% | 57% |
| Avg Move | +7.8% | +20.3% | +43.3% |
| Alpha | +6.3% | +17.0% | +34.2% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| FBRX | BUY | 2023-12-18 | 2023-12-20 | $0.75 | $8K | +15.7% | -2.8% | -8.0% |
| FBRX | BUY | 2023-12-13 | 2023-12-15 | $0.71 | $15K | -1.2% | -9.3% | -16.8% |
| FBRX | BUY | 2023-12-11 | 2023-12-12 | $0.65 | $19K | +9.5% | +10.4% | +4.2% |
| FBRX | BUY | 2023-12-07 | 2023-12-08 | $0.59 | $30K | +15.6% | +29.9% | +20.3% |
| FBRX | BUY | 2023-11-20 | 2023-11-22 | $0.44 | $3K | +10.1% | +65.7% | +55.7% |
| FBRX | BUY | 2022-12-15 | 2022-12-19 | $1.04 | $162K | +1.1% | +2.1% | -0.5% |
| FBRX | SELL | 2021-09-07 | 2021-09-08 | $4.35 | $4.3M | -13.8% | -30.3% | -36.9% |
| FBRX | BUY | 2020-06-25 | 2020-06-29 | $14.48 | $101K | +3.4% | +46.4% | +248.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.